Alemtuzumab was initially used with some success to treat several cohorts of refractory RA patients in the early 1990s; however, given the resultant profound lymphopenia, particularly in the CD4+ compartment, trials in RA were curtailed [1]. This evidence concerns the gene CD4 and rheumatoid arthritis.